A randomized Trial of recombinant human granulocyte-macrophage colony stimulating factor for Patients with acute lung injury

Critical Care Medicine

Volumn 40, Issue 1, 2012, Pages 90-97

  Paine, Robert ^a,b,g   Standiford, Theodore J ^a   Dechert, Ronald E ^a   Moss, Marc ^d   Martin, Gregory S ^f   Rosenberg, Andrew L ^b   Thannickal, Victor J ^a,h   Burnham, Ellen L ^e   Brown, Morton B ^c   Hyzy, Robert C ^a  

^a Division of Pulmonary and Critical Care Medicine   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^d VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^h University of Alabama at Birmingham   (United States)

Author keywords

Acute respiratory distress syndrome; Growth factors; Innate immunity; Sepsis

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 6; INTERLEUKIN 8; PLACEBO; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LUNG INJURY; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; ARTIFICIAL VENTILATION; BREATHING; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE DURATION; DISEASE FREE INTERVAL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GAS EXCHANGE; HUMAN; INFECTION; LEUKOCYTE COUNT; LEUKOCYTOSIS; LUNG DISEASE; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT; OXYGENATION; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SEPSIS; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VENTILATOR;

ACUTE LUNG INJURY; BRONCHOALVEOLAR LAVAGE FLUID; DOUBLE-BLIND METHOD; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INFUSIONS, INTRAVENOUS; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; RESPIRATION, ARTIFICIAL; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84055173351     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31822d7bf0     Document Type: Article

References (31)

1. Ware LB, Matthay MA: The acute respiratory distress syndrome. N Engl J Med 2000; 342: 1334-1349
2. Rubenfeld GD, Caldwell E, Peabody E, et al: Incidence and outcomes of acute lung injury. N Engl J Med 2005; 353:1685-1693
3. Ashbaugh DG, Bigelow DB, Petty TL, et al: Acute respiratory distress in adults. Lancet 1967; 2:319-323
4. Steinberg KP, Hudson LD: Acute lung injury and acute respiratory distress syndrome. The clinical syndrome. Clin Chest Med 2000; 21: 401-417, vii
5. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network N Engl J Med 2000 342 1301-1308
6. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Wiedemann HP, Wheeler AP, et al: Comparison of two fluidmanagement strategies in acute lung injury. N Engl J Med 2006; 354:2564-2575
7. Davidson TA, Caldwell ES, Curtis JR, et al: Reduced quality of life in survivors of acute respiratory distress syndrome compared with critically ill control patients. JAMA 1999; 281:354-360
8. Schelling G, Stoll C, Vogelmeier C, et al: Pulmonary function and health-related quality of life in a sample of long-term survivors of the acute respiratory distress syndrome. Intensive Care Med 2000; 26:1304-1311
9. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: A randomized controlled trial. The ARDS Network. JAMA 2000; 283: 1995-2002
10. Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome Crit Care Med 2002 30 1-6
11. Trapnell BC, Whitsett JA: Gm-CSF regulates pulmonary surfactant homeostasis and alveolar macrophage-mediated innate host defense. Annu Rev Physiol 2002; 64:775-802
12. Paine R 3rd, Wilcoxen SE, Morris SB, et al: Transgenic overexpression of granulocyte macrophage-colony stimulating factor in the lung prevents hyperoxic lung injury. Am J Pathol 2003; 163:2397-2406
13. Huffman Reed JA, Rice WR, Zsengellér ZK, et al: GM-CSF enhances lung growth and causes alveolar type II epithelial cell hyperplasia in transgenic mice. Am J Physiol 1997; 273:L715-L725
14. Matute-Bello G, Liles WC, Radella F 2nd, et al: Modulation of neutrophil apoptosis by granulocyte colony-stimulating factor and granulocyte/macrophage colony-stimulating factor during the course of acute respiratory distress syndrome. Crit Care Med 2000; 28:1-7
15. Baleeiro CE, Christensen PJ, Morris SB, et al: GM-CSF and the impaired pulmonary innate immune response following hyperoxic stress. Am J Physiol Lung Cell Mol Physiol 2006; 291:L1246-L1255
16. Bernard GR, Artigas A, Brigham KL, et al: The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994; 149: 818-824
17. Martin GS, Mannino DM, Moss M: The effect of age on the development and outcome of adult sepsis. Crit Care Med 2006; 34:15-21
18. Brower RG, Lanken PN, MacIntyre N, et al: Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med 2004; 351:327-336
19. Moore BB, Coffey MJ, Christensen P, et al: GM-CSF regulates bleomycin-induced pulmonary fibrosis via a prostaglandin-dependent mechanism. J Immunol 2000; 165: 4032-4039
20. Brun-Buisson C, Minelli C, Bertolini G, et al: Epidemiology and outcome of acute lung injury in European intensive care units. Results from the ALIVE study. Intensive Care Med 2004; 30:51-61
21. Uchida K, Nakata K, Suzuki T, et al: Granulocyte/macrophage-colony- stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects. Blood 2009; 113:2547-2556
22. Munoz C, Carlet J, Fitting C, et al: Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 1991; 88:1747-1754
23. Baleeiro CE, Wilcoxen SE, Morris SB, et al: Sublethal hyperoxia impairs pulmonary innate immunity. J Immunol 2003; 171:955-963
24. Wang QR, Wang F, Zhu WB, et al: GM-CSF accelerates proliferation of endothelial progenitor cells from murine bone marrow mononuclear cells in vitro. Cytokine 2009; 45:174-178
25. Cho HJ, Kim HS, Lee MM, et al: Mobilized endothelial progenitor cells by granulo-cyte-macrophage colony-stimulating factor accelerate reendothelialization and reduce vascular inflammation after intravascular radiation. Circulation 2003; 108: 2918-2925
26. Rojas M, Xu J, Woods CR, et al: Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol 2005; 33:145-152
27. Németh K, Leelahavanichkul A, Yuen PS, et al: Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009; 15:42-49
28. Nierhaus A, Montag B, Timmler N, et al: Reversal of immunoparalysis by recombinant human granulocyte-macrophage colonystimulating factor in patients with severe sepsis. Intensive Care Med 2003; 29:646-651
29. Orozco H, Arch J, Medina-Franco H, et al: Molgramostim (GM-CSF) associated with antibiotic treatment in nontraumatic abdominal sepsis: A randomized, double-blind, placebo-controlled clinical trial. Arch Surg 2006; 141:150-153; discussion 154
30. Presneill JJ, Harris T, Stewart AG, et al: A randomized phase II trial of granulocytemacrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am J Respir Crit Care Med 2002; 166: 138-143
31. Meisel C, Schefold JC, Pschowski R, et al: Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: A double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009; 180:640-648